Capecitabine

Capecitabine 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Breast Neoplasms、Metastatic Colorectal Carcinoma、Metastatic Malignant Solid Neoplasm、Stage IV Colorectal Cancer AJCC v8。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Capecitabine 研究

• SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC

  II 期招募中中国NCT07284992

• Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

  II 期招募中中国NCT06121700

• A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

  II 期招募中中国NCT06767800

• Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

  II 期招募中中国NCT06928584

• A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

  III 期招募中德国NCT06643585

• PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

  II 期招募中美国NCT06245889

• NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

  II 期招募中中国NCT06405490

• The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer

  IV 期招募中中国NCT06368063

• AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

  II 期招募中中国NCT06196697

• Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

  II 期招募中中国NCT05671822

• Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

  III 期招募中South KoreaNCT04787354

• AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

  II 期招募中中国NCT06494995

• Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.

  II 期招募中德国IsraelNCT06940388

• IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

  I 期 / II 期招募中中国NCT07692750

• MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

  II 期招募中中国NCT06840665

• Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer

  II 期招募中中国NCT07108127

• Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients

  不适用招募中EgyptNCT06765252

• Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

  II 期招募中法国NCT05973864

• DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

  III 期招募中荷兰NCT06275958

• The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

  IV 期招募中中国NCT06217185

• Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

  I 期 / II 期招募中美国NCT07456852

• A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.

  II 期招募中中国NCT07788196

• UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer

  IV 期招募中中国NCT05148767

• SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis

  II 期招募中中国NCT07384234

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。